

# Merit Medical Denmark A/S

Onsgårds Tværvvej 6, kl.


2900 Hellerup

CVR No. 30076478

## Annual Report 2023

17. financial year

The Annual Report was presented and  
adopted at the Annual General Meeting of  
the Company on 24 April 2024



Fred Peter Lampropoulos  
Chairman

**Merit Medical Denmark A/S**

**Contents**

Management's Statement	3
Independent Auditors' Report	4
Company Information	6
Management's Review	7
Accounting Policies	8
Income Statement	11
Balance Sheet	12
Notes	14

**Merit Medical Denmark A/S**

**Management's Statement**

Today, Management has considered and adopted the Annual Report of Merit Medical Denmark A/S for the financial year 1 January 2023 - 31 December 2023.

The Annual Report is presented in accordance with the Danish Financial Statements Act.

In our opinion, the Financial Statements give a true and fair view of the assets, liabilities and financial position of the Company at 31 December 2023 and of the results of the Company's operations for the financial year 1 January 2023 - 31 December 2023.

In our opinion, the Management's Review includes a true and fair account of the matters addressed in the review.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Gentofte, 24 April 2024

**Executive Board**

Mark Valentine Butler

**Supervisory Board**

  
Fred Peter Lampropoulos  
Chairman

  
Brian Glen Lloyd

Mark Valentine Butler

## Management's Statement

Today, Management has considered and adopted the Annual Report of Merit Medical Denmark A/S for the financial year 1 January 2023 - 31 December 2023.

The Annual Report is presented in accordance with the Danish Financial Statements Act.

In our opinion, the Financial Statements give a true and fair view of the assets, liabilities and financial position of the Company at 31 December 2023 and of the results of the Company's operations for the financial year 1 January 2023 - 31 December 2023.

In our opinion, the Management's Review includes a true and fair account of the matters addressed in the review.

We recommend that the Annual Report be adopted at the Annual General Meeting.

Gentofte, 24 April 2024

### Executive Board



Mark Valentine Butler

### Supervisory Board

Fred Peter Lampropoulos  
Chairman

Brian Glen Lloyd



Mark Valentine Butler

## Independent Auditors' Report

To the shareholder of Merit Medical Denmark A/S

### Opinion

We have audited the financial statements of Merit Medical Denmark A/S for the financial year 1 January 2023 - 31 December 2023, which comprise an income statement, balance sheet and notes. The financial statements are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the Company's financial position at 31 December 2023 and of the results of its operations for the financial year 1 January 2023 - 31 December 2023 in accordance with the Danish Financial Statements Act.

### Basis of opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs) and additional requirements applicable in Denmark. Our responsibility under those standards and requirements are further described in the "Auditors' responsibility for the Audit of the Financial Statements" section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Independence

We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (including International Independence Standards) (IESBA Code) together with the ethical requirements that are relevant to our audit of the financial statement in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code.

### Management's responsibility for the financial statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act and for such internal control as Management considers necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern; disclosing, as applicable, matters related to going concern; and using the going concern basis of accounting in preparing the financial statements unless Management either intends to either liquidate the Company or suspend operations, or has no realistic alternative but to do so.

### The auditor's responsibility for the audit of the financial statements

Our responsibility is to obtain reasonable assurance as to whether the financial statements are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is no guarantee that an audit conducted in accordance with ISAs and additional requirements applicable in Denmark will always detect material misstatements. Misstatements can arise from fraud or error and can be considered material if it would be reasonable to expect that these - either individually or collectively - could influence the economic decisions taken by the users of financial statements on the basis of these financial statements.

As part of an audit conducted in accordance with ISAs and additional requirements applicable in Denmark, we exercise professional judgement and maintain an attitude of professional skepticism throughout the audit. We also:

- \* Identify and assess the risk of material misstatements in the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for a material misstatement resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations or override of internal control.

## Independent Auditors' Report

- \* Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- \* Evaluate whether the accounting policies used are appropriate and whether the accounting estimates and the related disclosures made by Management are reasonable.
- \* Conclude on whether Management's use of the going concern basis of accounting in preparing the financial statements is appropriate and, based on the audit evidence obtained, conclude on whether a material uncertainty exists relating to events or conditions, which could cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may imply that the Company can no longer remain a going concern.
- \* Evaluate the overall presentation, structure and contents of the financial statements, including note disclosures, and whether the financial statements reflect the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control which we identify during our audit.

### Statement on Management's Review

Management is responsible for the Management's review.

Our opinion on the financial statements does not cover the Management's review, and we do not express any form of opinion providing assurance regarding the Management's review.

Our responsibility in connection with our audit of the financial statements is to read the Management's review and, in doing so, consider whether the Management's review is materially inconsistent with the financial statements or with the knowledge we have gained during the audit, or otherwise appears to be materially misstated.


Moreover, it is our responsibility to consider whether the Management's review meets the disclosure requirements in the Danish Financial Statements Act.

Based on our procedures, we are of the opinion that the Management's review is in accordance with the financial statements and has been prepared in accordance with the requirements in the Danish Financial Statements Act. In our opinion, the Management's review is not materially misstated.

Copenhagen, 24 April 2024

**Deloitte Statsautoriseret Revisionspartnerselskab**

CVR-no. 33963556



Flemming Larsen

State Authorised Public Accountant

mne27790

## Merit Medical Denmark A/S

### Company details

<b>Company</b>	Merit Medical Denmark A/S Onsgårds Tværvej 6, kl. 2900 Hellerup
CVR No.	30076478
Date of formation	1 December 2006
Registered office	Gentofte
Financial year	1 January 2023 - 31 December 2023
<b>Supervisory Board</b>	Fred Peter Lampropoulos Brian Glen Lloyd Mark Valentine Butler
<b>Executive Board</b>	Mark Valentine Butler
<b>Auditors</b>	Deloitte Statsautoriseret Revisionspartnerselskab Weidekampsgade 6 2300 København S CVR-no.: 33963556

## Management's Review

### The Company's principal activities

The Company's principal activities consist in sale and distribution of medical equipment to hospitals and other treatment centres.

### Development in activities and the financial situation

The Company's Income Statement of the financial year 1 January 2023 - 31 December 2023 shows a result of DKK 2.469.496 and the Balance Sheet at 31 December 2023 a balance sheet total of DKK 20.078.851 and an equity of DKK 11.933.373.

Sales increased compared to FY 2022 and were in line with budget projections for FY 2023 and in line with expectations.

### Post financial year events

After the end of the financial year, no events have occurred which may change the financial position of the entity substantially.

### Expectations for the future

We are optimistic that we can maintain the level of growth and continue to increase sales in FY 2024 compared to prior year FY 2023. Sales for 2024 are in line with projections to-date. We continue to maintain strong control over costs.



## Merit Medical Denmark A/S

### Accounting Policies

#### Reporting Class

The annual report of Merit Medical Denmark A/S for 2023 has been presented in accordance with the provisions of the Danish Financial Statements Act applying to enterprises of reporting class B.

The accounting policies applied remain unchanged from last year.

#### Reporting currency

The annual report is presented in Danish kroner.

#### Translation policies

Transactions in foreign currencies are translated into DKK at the exchange rate prevailing at the date of transaction. Monetary assets and liabilities in foreign currencies are translated into DKK based on the exchange rates prevailing at the balance sheet day. Realised and unrealised foreign exchange gains and losses are included in the income statement under financial income and expenses.

### Income statement

#### Gross profit or loss

Gross profit or loss comprises revenue, change in inventories of finished goods, other operating income, costs of raw materials and consumables and other external expenses.

#### Revenue

Income from the sale of goods for resale and finished goods is recognised in the income statement if the goods have been delivered and the risk has passed to the buyer before year-end if it is possible to calculate the income reliably. The revenue is exclusive of VAT and net of sales discounts.

#### Other external expenses

Other external expenses include expenses for distribution, sales, advertising, administration, premises, bad debts, operating leasing expenses etc.

#### Amortisation and impairment of tangible and intangible assets

Amortization and impairment of intangible assets, property, plant and equipment has been performed based on a continuing assessment of the useful life of the assets in the Company. Non-current assets are amortized on a straight line basis, based on cost, on the basis of the following assessment of useful life and residual values:

	<b>Useful life</b>
Other fixtures and fittings, tools and equipment	3-5 years

Profit or loss resulting from the sale of intangible assets or property, plant and equipment is determined as the difference between the selling price less selling costs and the carrying amount at the date of sale, and is recognised in the income statement under other operating income or expenses.

#### Financial income and expenses

Financial income and expenses are recognised in the income statement based at the amounts that concern the financial year. Financial income and expenses include interest income and expenses and realised and unrealised capital gains and losses regarding transactions in foreign currencies.

#### Tax on net profit for the year

Tax on net profit for the year comprises current tax on expected taxable income of the year and the year's adjustment of deferred tax less the part of the tax of the year that relates to changes in equity. Current and deferred tax regarding changes in equity is recognised directly in equity.

## Accounting Policies

### Balance sheet

#### Tangible assets

Tangible assets are measured at cost on initial recognition and subsequently at cost less accumulated depreciation and impairment losses.

The depreciable amount is calculated taking into consideration the residual value of the asset at the end of its useful life, reduced by impairment losses, if any. The depreciation period and the residual value are determined at the date of acquisition. If the residual value exceeds the carrying amount of the asset, depreciation is discontinued.

In case of changes in depreciation period or residual value, the effect of a change in depreciation period is recognised prospectively in accounting estimates.

Cost includes the purchase price and expenses directly related to the acquisition until the time when the asset is ready for use.

Tangible assets that are leased and meet the conditions for financial leasing are treated according to the same guidelines as those applying to purchased assets.

The cost of financially leased assets is measured at the lower value of the purchase prices according to the leases and the present value of the lease payments, determined on the basis of the interest rate implicit in the leases.

#### Inventories

The cost of goods for resale and consumables are measured at cost, comprising purchase price plus delivery costs.

#### Receivables

Receivables are measured at amortized cost which usually corresponds to the nominal value. The value is reduced by write-downs for expected bad debts.

Impairment of accounts receivables past due is established on individual assessment of receivables.

#### Prepaid expenses

Prepaid expenses recognised in assets comprises prepaid costs regarding subsequent financial years. Prepayments are measured at cost.

#### Equity

Equity comprises the working capital and a number of equity items that may be statutory or stipulated in the articles of association.

#### Deferred tax

Deferred tax and the associated adjustments for the year are determined according to the liability method as the tax base of all temporary differences between carrying amounts and the tax bases of assets and liabilities.

Deferred tax assets, including the tax base of tax losses allowed for carryforward, are recognised at the value at which they are expected to be used, either by elimination in tax on future earnings or by set-off against deferred tax liabilities in enterprises within the same legal entity and jurisdiction.

Deferred tax is measured on the basis of the tax rules and tax rates that will be effective under the legislation applicable at the balance sheet date when the deferred tax is expected to crystallize as current tax.

#### Current tax liabilities

Current tax liabilities and current tax receivables are recognised in the balance sheet as estimated income tax charge for the year, adjusted for prior-year taxes and tax paid on account.

## **Accounting Policies**

### **Liabilities**

Other liabilities are measured at net realisable value.

### **Lease commitments**

Lease commitments are measured at the present value of the remaining lease payments including any guaranteed residual value based on the interest rate implicit in the individual leases.

### **Accruals and deferred income entered as liabilities**

Accruals and deferred income entered as liabilities consist of payments received regarding income in the subsequent financial years.

### **Contingent assets and liabilities**

Contingent assets and liabilities are not recognised in the Balance Sheet but appear only in the notes.

Merit Medical Denmark A/S

**Income Statement**

	Note	2023 kr.	2022 kr.
<b>Gross profit</b>		<b>8.049.743</b>	<b>6.264.944</b>
Employee benefits expenses	1	-5.123.691	-4.960.816
Depreciation, amortisation expense and impairment losses of property, plant and equipment		-13.881	-9.672
<b>Profit from ordinary operating activities</b>		<b>2.912.171</b>	<b>1.294.456</b>
Finance income from group enterprises		23.073	23.661
Other financial income	2	270.161	19.896
Other financial expenses	3	-19.468	-70.414
<b>Profit from ordinary activities before tax</b>		<b>3.185.937</b>	<b>1.267.599</b>
Tax expense on ordinary activities	4	-716.441	-290.487
<b>Profit</b>		<b>2.469.496</b>	<b>977.112</b>
<b>Proposed distribution of results</b>			
Retained earnings		2.469.496	977.112
<b>Distribution of profit</b>		<b>2.469.496</b>	<b>977.112</b>

Merit Medical Denmark A/S

Balance Sheet as of 31 December

	Note	2023 kr.	2022 kr.
<b>Assets</b>			
Fixtures, fittings, tools and equipment	5	22.991	26.485
<b>Property, plant and equipment</b>		<b>22.991</b>	<b>26.485</b>
<b>Fixed assets</b>		<b>22.991</b>	<b>26.485</b>
Raw materials and consumables		171.444	165.644
<b>Inventories</b>		<b>171.444</b>	<b>165.644</b>
Short-term trade receivables		7.428.447	9.975.964
Short-term receivables from group enterprises		3.497.910	3.432.851
Other short-term receivables		120.863	86.610
Prepaid expenses		62.013	107.397
<b>Receivables</b>		<b>11.109.233</b>	<b>13.602.822</b>
<b>Cash and cash equivalents</b>		<b>8.775.183</b>	<b>8.642.123</b>
<b>Current assets</b>		<b>20.055.860</b>	<b>22.410.589</b>
<b>Assets</b>		<b>20.078.851</b>	<b>22.437.074</b>

Merit Medical Denmark A/S

Balance Sheet as of 31 December

	Note	2023 kr.	2022 kr.
<b>Liabilities and equity</b>			
Contributed capital		500.000	500.000
Retained earnings		11.433.373	8.963.878
<b>Equity</b>		<b>11.933.373</b>	<b>9.463.878</b>
Trade payables		286.409	197.616
Payables to group enterprises		3.825.058	7.860.559
Tax payables		454.823	60.546
Other payables		3.579.188	4.854.475
<b>Short-term liabilities other than provisions</b>		<b>8.145.478</b>	<b>12.973.196</b>
<b>Liabilities other than provisions within the business</b>		<b>8.145.478</b>	<b>12.973.196</b>
<b>Liabilities and equity</b>		<b>20.078.851</b>	<b>22.437.074</b>
Contingent liabilities	6		
Collaterals and assets pledged as security	7		
Ownership	8		
Liabilities under off-balance sheet leases	9		
Related parties	10		
Other disclosures	11		

## Merit Medical Denmark A/S

### Notes

#### 1. Employee benefits expense

	2023	2022
Wages and salaries	4.630.589	4.134.251
Post-employment benefit expense	346.924	277.567
Social security contributions	29.069	17.003
Other employee expense	117.109	531.995
	<u>5.123.691</u>	<u>4.960.816</u>

Average number of employees	<u>4</u>	<u>3</u>
-----------------------------	----------	----------

#### 2. Other financial income

Interest Income	174.469	19.896
Realized FX Gain/Loss	94.878	0
Unrealized FX Gain/Loss	814	0
	<u>270.161</u>	<u>19.896</u>

#### 3. Other financial expenses

Bank Charges	16.248	70.319
Gain/Loss Foreign Exc Rates	0	95
Interest Expense	3.220	0
	<u>19.468</u>	<u>70.414</u>

#### 4. Tax expense

Adjustment to prior years	-382	-6.059
Income Taxes	716.823	296.546
	<u>716.441</u>	<u>290.487</u>

#### 5. Fixtures, fittings, tools and equipment

Cost at the beginning of the year	45.417	60.954
Addition during the year, incl. improvements	10.387	62.419
Disposal during the year	-8.043	-29.475
Transfers during the year to other items	0	-48.481
<b>Cost at the end of the year</b>	<u>47.761</u>	<u>45.417</u>

Depreciation and amortisation at the beginning of the year	-18.932	-46.316
Amortisation for the year	-13.881	-9.672
Reversal of impairment losses and amortisation of disposed assets	8.043	37.056
<b>Impairment losses and amortisation at the end of the year</b>	<u>-24.770</u>	<u>-18.932</u>

<b>Carrying amount at the end of the year</b>	<u>22.991</u>	<u>26.485</u>
---	---------------	---------------

## **Merit Medical Denmark A/S**

### **Notes**

#### **6. Contingent liabilities**

No contingent liabilities exist at the balance sheet date.

#### **7. Collaterals and securities**

No securities or mortgages exist at the balance sheet date.

#### **8. Ownership**

Related parties with a controlling interest in Merit Medical Denmark A/S:

\* The Parent Company: Merit Holdings Inc., 1600 West Merit Parkway, South Jordan Utah 84095 USA.

\* The Ultimate Parent Company: Merit Medical Systems, Inc. 1600 West Merit Parkway, South Jordan Utah 84095 USA

#### **9. Liabilities under leases**

Total liability for operation lease contracts on cars at the balance sheet date amounts to DKK 427,880 (2022: DKK 238,701)

#### **10. Related parties**

There have been no transactions with the Supervisory Board, the Executive Board, senior officers, significant shareholders, group enterprises or other related parties, except for normal intercompany transactions carried out on market conditions.

#### **11. Consolidation**

Merit Medical Denmark A/S is included in the consolidated financial statements of Merit Medical Systems, Inc. 1600 West Merit Parkway, South Jordan UT 84095, USA, from which copies of the consolidated financial statements may be obtained.